Hydroxychloroquine Market

The new coronavirus is believed to be responsible for 2 million COVID-19 active cases as of April 2020, along with an estimated 126,758 related deaths. The WHO classified COVID-19 to be a pandemic in March 2020. Healthcare regulators have been forced to approve other pharmaceuticals for illness control and management because there is no specific therapeutic therapy for COVID-19 on the market, and the vaccination will take longer than 18 months to reach the market. Hydroxychloroquine demonstrated one such promise. In several studies, the medication was administered to COVID-19 patients in China, France, and the United States.

The outcomes of patients who received this medication showed promise. This prompted the U.S. FDA to grant the medication Emergency Use Authorization (EUA) in oral formulation for COVID-19 patients. This increase in demand is anticipated to support hydroxychloroquine's market expansion.

In Asia Pacific's emerging nations, there has been an upsurge in the prevalence of malaria over the past few years. According to estimates, India has the most malaria cases in the area. One of the most popular medications in the nation for treating malaria is hydroxychloroquine. According to information from the World Malaria Report 2019, 6 million people in India alone had malaria diagnoses. The World Health Organisation (WHO) estimates that 228 million people worldwide contracted malaria in 2018. In addition, the spread of malaria in developing and underdeveloped nations has been accelerated by mosquitoes that are resistant to pesticides.

This industry is expected to expand favourably during the forecast period despite the rise in malaria cases and pesticide resistance among vectors.

It is predicted that the market would experience significant growth due to increased generic medicine penetration and rising demand for new hydroxychloroquine. Additionally, higher product approval is anticipated to have a significant impact on the industry thanks to increased government spending. The influx of new generic pharmaceuticals and rising patient knowledge of COVID-19 are expected to hasten the uptake of hydroxychloroquine medications. According to Johns Hopkins University, as of April 15, 2020, only the US had 609,516 cases with COVID-19.

Revenue growth is anticipated to be aided by rising clinical trials to assess the efficacy of hydroxychloroquine in the treatment of COVID-19 and growing awareness of disease remittance therapies. Thus, driving the Hydroxychloroquine market revenue.

Government initiatives and funding play a crucial role in shaping the Global Hydroxychloroquine Market Industry. Various governments are allocating resources to support the development and distribution of hydroxychloroquine, particularly in low-income countries where access to essential medications is limited. These initiatives often include subsidies, grants, and partnerships with pharmaceutical companies to ensure a steady supply of hydroxychloroquine. Such efforts not only enhance the drug's availability but also contribute to public health goals. As governments prioritize healthcare access, the market is expected to witness sustained growth, driven by these supportive policies.

The Global Hydroxychloroquine Market Industry is poised for growth in emerging markets, where economic development is leading to increased healthcare spending. Countries in Asia and Africa are experiencing improvements in healthcare infrastructure, which facilitates better access to medications like hydroxychloroquine. As these regions invest in healthcare, the demand for effective treatments is likely to rise. This trend is supported by a growing middle class that prioritizes health and wellness. Consequently, the market may see a substantial increase in sales, reflecting the broader economic growth and the need for reliable healthcare solutions.

The Global Hydroxychloroquine Market Industry experiences a notable increase in demand for antimalarial drugs, particularly in regions where malaria remains endemic. Hydroxychloroquine is recognized for its efficacy in treating malaria, which contributes to its sustained relevance in public health. In 2024, the market is valued at approximately 0.2 USD Billion, reflecting the ongoing need for effective treatments. This demand is further driven by initiatives from global health organizations aimed at eradicating malaria, which may enhance the visibility and availability of hydroxychloroquine. As awareness of malaria prevention grows, the market is likely to expand significantly.

The Global Hydroxychloroquine Market Industry is significantly influenced by the increasing awareness of autoimmune disorders. Conditions such as rheumatoid arthritis and lupus are gaining recognition, leading to a higher demand for effective treatments. Hydroxychloroquine is a cornerstone in managing these diseases, and as more patients seek diagnosis and treatment, the market is likely to expand. Educational campaigns and advocacy from patient organizations are instrumental in raising awareness, which may result in a larger patient population requiring hydroxychloroquine. This trend suggests a promising future for the market as it aligns with the growing focus on chronic disease management.

The Global Hydroxychloroquine Market Industry benefits from heightened research and development activities aimed at exploring new therapeutic applications of hydroxychloroquine. Researchers are investigating its potential use in various autoimmune diseases, which could broaden its market scope. The ongoing studies may lead to innovative formulations and delivery methods, enhancing patient compliance and treatment outcomes. As a result, the market is projected to grow at a compound annual growth rate of 27.13% from 2025 to 2035. This growth trajectory indicates a robust interest in hydroxychloroquine, potentially leading to a market valuation of 2.8 USD Billion by 2035.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific Hydroxychloroquine market dominated this market in 2022 (45.80%). Due to a lack of disease awareness in some developing nations, the number of sufferers is rising in such nations. This, together with increased healthcare spending, the presence of significant manufacturers like Zydus, Cadila, Novartis, and Sun Pharmaceuticals, and an increase in product approvals, are all expected to boost the market in APAC.

During the projected period, the regional markets are expected to grow due to the rising need for target drugs for disease reversal. Moreover, China’s market of Hydroxychloroquine held the largest market share, and the Indian market of Hydroxychloroquine was the fastest growing market in the Asia-Pacific region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HYDROXYCHLOROQUINE MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The North America Hydroxychloroquine Market is expected to register significant growth from 2024 to 2032. The region is expanding as a result of increased patient awareness of disease remitted therapy, an increase in the prevalence of RA and COVID-19, and high public and private healthcare spending. Furthermore, the World Health Organisation predicts that 54.4 million adults in the nation may have rheumatoid arthritis by the end of 2040. Additionally, it is anticipated that simple access to high-quality healthcare, kind reimbursement systems, a robust trial pipeline, and the approval of innovative pharmaceuticals will support revenue growth in North America.

Further, the U.S. market of Hydroxychloroquine held the largest market share, and the Canada market of Hydroxychloroquine was the fastest growing market in the North America region.

Europe Hydroxychloroquine market accounted for the healthy market share in 2022. The market in Europe is anticipated to grow as a result of government restrictions, the availability of large-scale research facilities, and medication safety awareness.Further, the German market of Hydroxychloroquine held the largest market share, and the U.K market of Hydroxychloroquine was the fastest growing market in the European region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Hydroxychloroquine, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Hydroxychloroquine Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Hydroxychloroquine Industry to benefit clients and increase the market sector. In recent years, the Hydroxychloroquine Industry has offered some of the most significant advantages to medicine.

Major players in the Hydroxychloroquine market, including Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Mylan N.V., Novartis International AG, Hikma Pharmaceuticals, Ipca Laboratories, Apotex Corporation, Cipla, Wallace Pharmaceuticals, Covis Pharmaceuticals Ltd., Lupin Pharmaceutical, McW Healthcare, Intas Pharmaceuticals, Macleods Pharmaceuticals, Hanlim Pharmaceutical, Concordia Healthcare, Taj Pharmaceuticals, Laurus Labs Limited, Shanghai Pharmaceuticals Holding, and Kyung Poong, are attempting to increase market demand by investing in research and development operations.

An integrated healthcare provider, Zydus Lifesciences Ltd. (Zydus Lifesciences) formerly known as Cadila Healthcare Ltd. It finds, creates, produces, and markets a range of medical items. Active pharmaceutical ingredients (APIs), formulations, wellness, and animal health products are all part of the company's product line. Products from Zydus Lifesciences are used to treat illnesses in a variety of therapeutic fields, including women's health, neurology, pain management, cancer, cardiovascular disease, and inflammation. It carries out studies to create vaccines, biologics, biosimilars, and novel chemical entities. The business has production facilities in Brazil, the US, Goa, Maharashtra, Sikkim, and Himachal Pradesh in India.

In addition to other emerging markets, it is present in the US, Europe, South Africa, Japan, and Brazil. The headquarters of Zydus Lifesciences are located in Ahmedabad, Gujarat, India. With the goal of increasing manufacturing capacity by 5–6 times to 70 MT per month by April 2020, Zydus Cadila and Ipca Labs have backward integrated HCQ making capability. This will increase the therapeutic options available to the millions of people who suffer from target diseases.

A healthcare firm called Novartis AG (Novartis) specialises in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. In addition to others, it offers medicines for the treatment of solid tumours, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. Through Sandoz, the business provides biosimilars and generic medications. Through the Novartis Institutes for BioMedical Research (NIBR), Novartis carries out research in a number of disease-related fields.

In the Americas, Europe, the Middle East, Africa, and Asia-Pacific, the corporation has a network of subsidiaries and offices. Basel, Switzerland serves as the headquarters of Novartis. For controlled clinical studies to assess the efficacy of hydroxychloroquine in individuals who have tested positive for coronavirus disease (COVID 19), Novartis International AG began shipping 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) in March 2020.